Post-induction treatment for acute myeloid leukemia: something change?
Until recently, improvement in terms of survival for patients with acute myeloid leukemia (AML) was achieved mostly in younger patients with dose intensification of conventional chemotherapy and a broadening use of allogeneic hematopoietic cell transplantation (allo-HCT) whereas the results remained...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
16 July 2021
|
| In: |
Current oncology reports
Year: 2021, Volume: 23, Issue: 9 |
| ISSN: | 1534-6269 |
| DOI: | 10.1007/s11912-021-01092-0 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s11912-021-01092-0
|
| Author Notes: | Sonia Jaramillo, Richard F. Schlenk |
| Summary: | Until recently, improvement in terms of survival for patients with acute myeloid leukemia (AML) was achieved mostly in younger patients with dose intensification of conventional chemotherapy and a broadening use of allogeneic hematopoietic cell transplantation (allo-HCT) whereas the results remained dismal and very stable in patients older than 60 years. The current review highlights the recent developments in standard intensive post-remission chemotherapy, evidence for the use of recently approved agents, and discusses the relevance of measurable residual disease (MRD) measurement in treatment adaptation. |
|---|---|
| Item Description: | Gesehen am 23.09.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1534-6269 |
| DOI: | 10.1007/s11912-021-01092-0 |